243 completed, 19 terminated, 12 recruiting, 5 unknown. 82 Phase 1, 68 Phase 2, 58 Phase 3, 37 Phase 4, 9 Not applicable.
Follow LEO Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris Delgocitinib - Central Centrifugal Cicatricial Alopecia, Lichen Planopilaris | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 30 | 2026-05-19 | 2026-07-10 |
| A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus Delgocitinib, Cream Vehicle - Lichen Sclerosus | Phase 3 | Recruiting | LEO Pharma | 652 | 2026-05-01 | 2026-10-13 |
| Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact tralokinumab - Atopic Dermatitis (Moderate-to-severe) Involving the Genital Region | Recruiting | University Hospital Schleswig-Holstein | 30 | 2025-10-20 | 2026-03-03 | |
| A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis Delgocitinib cream, Vehicle cream - Palmoplantar Pustulosis | Phase 2 | Recruiting | LEO Pharma | 135 | 2025-09-11 | 2026-10-01 |
| Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis Thrombin Generation Assay (TGA) - Cancer, Pulmonary Embolism | Not applicable | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 212 | 2025-09-02 | 2026-08-24 |
| Real-World Evidence: Effectiveness and Safety of Chronic Hand Eczema Treatment With Delgocitinib Cream Chronic Hand Eczema (CHE) | Enrolling by invitation | LEO Pharma | 1000 | 2025-06-01 | 2026-05-22 | |
| A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum Spesolimab, Placebo matching to spesolimab, Prednisone - Pyoderma Gangrenosum | Phase 3 | Recruiting | LEO Pharma | 90 | 2025-02-05 | 2026-10-23 |
| Immune Signature of Chronic Hand Eczema Unveiled by Spatial Transcriptomics and Single-Cell Proteomics comprhensive spatial transcriptomic profile on lesional skin biopsies - Hand Eczema | Not applicable | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 40 | 2025-01-13 | 2025-03-19 |
| A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968 LEO 158968 - Joint Pain, Gout Flares | Phase 1 | Completed | LEO Pharma | 6 | 2025-01-07 | 2026-05-12 |
| A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis Tralokinumab + TCS, Placebo + TCS - Atopic Dermatitis | Phase 3 | Recruiting | LEO Pharma | 195 | 2024-06-10 | 2026-07-07 |
| A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares Spesolimab - Generalized Pustular Psoriasis | Phase 4 | Completed | LEO Pharma | 42 | 2023-10-22 | 2026-10-26 |
| A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis LEO 138559, Placebo - Atopic Dermatitis | Phase 2 | Completed | LEO Pharma | 262 | 2023-09-20 | 2026-02-12 |
| Tralokinumab for Dupilumab Failures tralokinumab - Atopic Dermatitis | Phase 4 | Terminated | Psoriasis Treatment Center of Central New Jersey | 7 | 2023-09-11 | 2026-05-22 |
| A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema Delgocitinib, Vehicle cream - Chronic Hand Eczema | Phase 3 | Completed | LEO Pharma | 362 | 2023-09-05 | 2025-09-25 |
| A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy Tralokinumab, Placebo - Atopic Dermatitis, Atopic Hand Eczema | Phase 3 | Completed | LEO Pharma | 235 | 2023-08-28 | 2026-10-22 |
| A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis LEO 90100, Daivobet® ointment - Stable Plaque Psoriasis | Phase 3 | Completed | LEO Pharma | 604 | 2023-06-21 | 2026-04-06 |
| Ophthalmological Adverse Events of Tralokinumab in AD Atopic Dermatitis | Completed | Nantes University Hospital | 100 | 2023-06-14 | 2026-05-01 | |
| TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer Tinzaparin - Colorectal Cancer Metastatic, Thromboembolism | Phase 3 | Completed | Galician Research Group on Digestive Tumors | 232 | 2023-03-02 | 2025-08-22 |
| Investigating the Safety of LEO 158968 in Healthy Volunteers LEO 158968, Placebo - Healthy | Phase 1 | Completed | LEO Pharma | 120 | 2023-02-07 | 2026-04-28 |
| Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT Tralokinumab - Atopic Dermatitis, Eczema | Recruiting | University of California, San Diego | 900 | 2022-12-08 | 2025-01-28 |
Showing 20 of 284. Sign in to see all of them.
Dermatitis, Atopic (44) · Keratosis, Actinic (40) · Psoriasis (20) · Venous Thrombosis (10) · Neoplasms (9) · Rosacea (8) · Venous Thromboembolism (8) · Thromboembolism (6) · Thrombosis (6) · Pulmonary Embolism (5) · Eczema (4) · Skin and Connective Tissue Diseases (4) · Acne Vulgaris (3) · Impetigo (3) · Multiple Myeloma (3)
calcipotriene (28) · 3-ingenyl angelate (22) · Tinzaparin (19) · tralokinumab (16) · betamethasone-17,21-dipropionate (13) · delgocitinib (9) · Gels (8) · Ointments (8) · betamethasone dipropionate, calcipotriol drug combination (8) · azelaic acid (7) · Betamethasone (6) · 2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide (5) · LEO 43204 (5) · brodalumab (5) · Clobetasol (4)
United States (86) · Germany (82) · France (69) · Canada (61) · United Kingdom (57) · Spain (32) · Poland (26) · Denmark (23) · Netherlands (23) · Belgium (20) · Japan (19) · Italy (18) · Australia (13) · China (9) · Sweden (9)
Catherine Queille-Roussel, MD (6) · Mark Lebwohl, MD (4) · Ashley Brooks, MD (3) · C. William Hanke, MD (3) · Gary Goldenberg, MD (3) · Joseph Chiesa, MD (3) · Patrice Facy, PhD (3) · Colin Fleming, MD (2) · Daniel M Siegel, MD (2) · Jerry Bagel, MD (2) · Masanari Shiramoto, MD., PhD (2)
PMID 40555305, PMID 41118053, PMID 32785881, PMID 34397196, PMID 36152216, PMID 40085349, PMID 33000465, PMID 37682422, PMID 37804473, PMID 38189593, PMID 38485862, PMID 39033766, PMID 40081663, PMID 40525591, PMID 41240207, PMID 41775339, PMID 42143645, PMID 10607349, PMID 11063900, PMID 15097955, PMID 16458642, PMID 17822489, PMID 18955209, PMID 19067709, PMID 19467365, PMID 19713451, PMID 20514316, PMID 20633284, PMID 20645521, PMID 21377137, PMID 21477846, PMID 21753882, PMID 22055282, PMID 22417254, PMID 22508869, PMID 22714759, PMID 23048011, PMID 23134268, PMID 23245654, PMID 23510990, PMID 23551034, PMID 23553119, PMID 23764005, PMID 23848131, PMID 23986161, PMID 24446656, PMID 24509965, PMID 24684267, PMID 24892649, PMID 24918567
2018 (9), 2017 (6), 2014 (5), 2008 (4), 2016 (4), 2023 (4), 2009 (3), 2019 (3), 2004 (1), 2015 (1), 2025 (1)